Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

FluMist is a nasally-administered influenza vaccine that is indicated for active immunization to prevent influenza disease in individuals 2 to 49 years of age.

The Food and Drug Administration (FDA) has approved Miplyffa ™ (arimoclomol) for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) ...

Three of the four states had corresponding evidence of human influenza activity from other surveillance systems ...

HealthDay News — After SARS-CoV-2 infection, prevalent metformin use is associated with a slightly lower incidence of death or postacute sequalae of SARS-CoV-2 (PASC), according to a study published ...

HealthDay News — Americans have the worst health care among the world’s wealthy nations, a new report says. People in the US die the earliest and live the sickest lives out of 10 developed countries, ...

Baloxavir marboxil significantly reduced the likelihood of influenza transmission from the infected patient to the household contacts. Treatment with baloxavir marboxil significantly reduced the risk ...

The over-the-counter medical application is intended for individuals aged 18 years and older who have not been previously diagnosed with sleep apnea.

HealthDay News — There are discrepancies between preferred and actual sources of contraceptive information for US adolescents and young adults (AYA), according to a research letter published online ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Reduced risk for Alzheimer disease, vascular dementia, and Parkinson disease seen with SGLT2i use in type 2 diabetes.

Safety profile similar to other trials, with six in 10 sustaining medication overuse headache remission over six months ...